Ab Initio CSO receives ISAM award
Ab Initio’s Chief Scientific Officer, Dr Hui Xin Ong (YY) has been awarded the prestigious Young Investigator Award at the 24th Congress of the International Society for Aerosols in Medicine (ISAM) in Saarbrücken, Germany. The award recognises YY’s International reputation as a early career researcher working in inhalation medicines.
Dr Ong has an outstanding track record in aerosol research and, as CSO at Ab Initio, she oversees the development and testing of orally and nasally inhaled nasal products for international clients which are then transferred into Ab Initio’s GMP manufacturing facility for human clinical trials.
YY’s research areas include, lab-on-a-chip models to evaluate toxicity, transport and effectiveness of aerosol products, formulation development of nasal and orally inhaled products, chemistry manufacturing and controls for regulatory submission and technical transfer for scale-up and manufacturing. YY also holds academic appointments at the Faculty of Medicine at Macquarie University and the Woolcock Institute, ranked no.1 globally for respiratory and sleep research.
ISAM is an international organisation, championing interdisciplinary exchange of aerosol research and information in medicine including health effects of inhaled aerosols & pulmonary drug delivery. You can learn more about ISAM here.
You can learn more about Ab Initio Pharma, our formulation R&D and GMP manufacturing services here.
